Revenue and Growth
Revenue for Q3 was $580 million, reflecting a total company growth of 7% on a constant currency basis or 6% on a reported basis. Consumables grew 9% on both constant currency and reported basis.
Strong Financial Performance
Adjusted EBITDA increased by 6% to $95 million compared to $90 million last year. Adjusted EPS was $1.59, slightly up from $1.57 last year.
Joint Venture with Otsuka
Announcement of a strategic joint venture with Otsuka Pharmaceutical Factory to enhance the IV Solutions business, expected to bring innovation and supply reliability to the market.
Cash Flow and Debt Reduction
Free cash flow was $16 million for the quarter, with plans to reduce accounts receivable factoring program utilization. Cash balance increased to $313 million, with plans to pay down debt significantly by the end of 2025.
FDA Inspection Success
A follow-up FDA inspection at the Minneapolis site was completed with no observations, marking a significant step in quality improvement efforts.